Roy R. Lobb

New England Biolabs (United States) — United States

Medicine · Health Sciences

60h-index16.9kcitations152works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell Adhesion Molecules Research(81), Monoclonal and Polyclonal Antibodies Research(38), CAR-T cell therapy research(21), Platelet Disorders and Treatments(19), Asthma and respiratory diseases(15)

Publications152 total

Expression-Dependent Tumor Pretargeting via Engineered Avidity
Molecular Pharmaceutics·2024· 2 cited
334 CAR T engagers encoding immune checkpoint inhibitors and immune-relevant cytokines stimulate CAR T cell activity against hematologic and solid tumors
Regular and Young Investigator Award Abstracts·2023Open Access
A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2+ Solid Cancer
Cells·2023· 3 citedOpen Access
175 CAR-T engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
Regular and Young Investigator Award Abstracts·2022Open Access
CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
OncoImmunology·2022· 5 citedOpen Access
Abstract 2759: CAR-T engager proteins for the treatment of B cell cancers and acute myeloid leukemia
Cancer Research·2022
CAR-T Engager Proteins Optimize Anti-CD19 CAR-T Cell Therapies for Lymphoma
2022Open Access
Characterization of Aleta-001, a CAR T Engager Designed to Optimize Responses and Prevent Relapses from CAR-19 Therapy
Blood·2021
160 Evaluation and development of dual and triple antigen targeting CAR-T Engager proteins for Her2-positive CNS metastases and solid tumors
Regular and Young Investigator Award Abstracts·2021· 1 citedOpen Access
Engineered protein-small molecule conjugates empower selective enzyme inhibition
Cell chemical biology·2021· 14 citedOpen Access
Engineered protein-small molecule conjugates empower selective enzyme inhibition
2021· 4 citedOpen Access
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
PLoS ONE·2021· 22 citedOpen Access
133 Development of novel cellular therapeutics for metastatic and primary CNS malignancies
Regular and Young Investigator Award Abstracts·2020Open Access
Adhesion Molecule Antagonists in Animal Models of Asthma
2020· 2 cited
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
2020Open Access
Abstract B020: CAR-CD19 T cells secreting multi-antigen bridging proteins eliminate solid tumors
Molecular Cancer Therapeutics·2019
A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment In Vivo
Blood·2019· 9 cited
Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design
Biochemistry·2019· 43 cited
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins
Molecular Pharmaceutics·2019· 41 cited
Abstract A040: Hijacking CAR19 T-cells for use in targeting diverse hematopoietic and solid tumors
Cancer Immunology Research·2019· 1 cited
page 1 of 8Next →

Frequent Co-authors

G Chi-Rosso(11), Christopher D. Benjamin(8), Catherine Hession(6), Diane R. Leone(6), Stefan Luhowskyj(5), Richard Tizard(5), James W. Fett(5), L Osborn(5), Barbara M. Newman(5), Susan Goelz(4), Martin E. Hemler(3), C Vassallo(3), Edward M. Alderman(3), Blake Pepinsky(3), Valentin Grabovsky(3), R. Alon(3), William M. Abraham(3), Steven P. Adams(3), Paul H. Weinreb(3), Cezary Marcinkiewicz(3)